Tag: greenlabs

07
Jun

Today in Cannabis

My Compassion, a nonprofit organization, prepares for the Chicago Cannabis Conference on Navy Pier this weekend. The first conference of its kind, speakers include: state representatives, doctors, lawyers, and industry professionals advocating the forward movement of responsibility and professionalism in a previously forbidden realm.

(http://www.chicagotribune.com/news/local/breaking/chi-cannabis-conference-at-navy-pier-this-weekend-20140606,0,981239.story)

The UK-based GW pharmaceuticals has announced plans to implement their product Epidiolex in US markets. Epidiolex is a cannabidiol (CBD) extract used to treat childhood epilepsy resulting from Dravet syndrome. Currently, Epidiolex is in use by only seven patients in the US under unique legal circumstances. As of today, the United States’ FDA has approved Epidiolex for “fast track designation”, which expedites the availability of breakthrough treatments.

(http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/10880133/GW-Pharmaceuticals-cannabis-based-drug-Epidiolex-to-be-fast-tracked-in-US.html)

 

 

02
Jun

Today in Cannabis

For over a decade, synthetic “herbal incense” designed to mimic the effects of cannabis has gained popularity due to the fact it’s been buyable in-store, and doesn’t show up on drug tests. It’s dangerous because synthetic cannabanoids have the potential to be much more potent than their organic counterparts. In addition, their non-regulation leaves much unknown about potential negative effects.

The reason volatile ‘analogs’ (like various versions of herbal incense) even exist, is cannabis prohibition. If the federal government doesn’t make serious amendments to drug policy, significant demand for herbal incense will remain.

(http://www.ladybud.com/2014/06/02/inside-the-issue-synthetic-marijuana-aka-herbal-incense/)

28
May

Back on Schedule

Virginia congressman Morgan Griffith presented HR 4498 earlier this month. “The Legitimate Use of Medicinal Marijuana Act” aims to federally reclassify cannabis from Schedule I to II. Before considering the disproportion related to legal consequence, only substances which have no medical value are placed under Schedule I; the key to this bill is security for medical establishments on a federal level.